Literature DB >> 20688449

Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study.

Mona A Mohamed1, Peter B Barker, Richard L Skolasky, Ola A Selnes, Richard T Moxley, Martin G Pomper, Ned C Sacktor.   

Abstract

BACKGROUND AND
PURPOSE: Human immunodeficiency virus (HIV)-associated dementia (HAD) has been extensively studied using magnetic resonance spectroscopy (MRS) at field strengths of 1.5 T. Higher magnetic field strengths (such as 3 T) allow for more reliable determination of certain compounds, such as glutamate (Glu) and glutamine (Gln). The current study was undertaken to investigate the utility of 3-T MRS for evaluating HIV+ patients with different levels of cognitive impairment with emphasis on the measurement of Glu and Glx (the sum of Glu and Gln).
METHODS: Eighty-six HIV+ subjects were evaluated at 3 T using quantitative short echo time single-voxel MRS of frontal white matter (FWM) and basal ganglia (BG). Subjects were divided into three groups according to the Memorial Sloan Kettering (MSK) HIV dementia stage: 21 had normal cognition (NC) (MSK 0), 31 had mild cognitive impairment (MCI) without dementia (clinical MSK stage=0.5), and 34 had dementia (HAD) (MSK≥1). HIV+ subjects had also undergone standardized cognitive testing covering the domains of executive function, verbal memory, attention, information processing speed and motor and psychomotor speed. Between-group differences in metabolite levels in FWM and BG were evaluated using ANOVA. Pearson correlation coefficients were used to explore the associations between the Glu and Glx metabolites and neurocognitive results.
RESULTS: FWM Glx was lower in HAD (8.1 ± 2.1 mM) compared to both the MCI (9.17 ± 2.1 mM) and NC groups (10.0 ± 1.6 mM) (P=.006). FWM myo-inositol (mI) was higher in HAD (4.15 ± 0.75 mM) compared to both MCI (3.86 ± 0.85 mM) and NC status (3.4 ± 0.67 mM) (P=.006). FWM Glx/creatine (Cr) was lower and FWM mI/Cr was significantly higher in the HAD compared to the MCI and NC groups (P=.01 and P=.004, respectively). BG N-acetyl aspartate (NAA) was lower in the HAD group (6.79 ± 1.53 mM), compared to the MCI (7.5 ± 1.06 mM) and NC (7.6 ± 1.01 mM) groups (P=.036). Significant negative correlations were observed between Glu, Glx and NAA concentrations with Trail-Making Test B (P=.006, P=.0001 and P=.007, respectively), and significant positive correlation was found with the Digit symbol test (P=.02, P=.002 and P=.008, respectively). FWM Glx and NAA concentrations showed negative correlation with Grooved Pegboard nondominant hand (P=.02 and P=.04, respectively).
CONCLUSION: Patients with HAD have lower levels of Glx concentrations and Glx/Cr ratio in FWM, which was associated with impaired performance in specific cognitive domains, including executive functioning, fine motor, attention and working memory performance. Three-Tesla MRS measurements of Glx may be a useful indicator of neuronal loss/dysfunction in patients with HIV infection.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688449      PMCID: PMC2963667          DOI: 10.1016/j.mri.2010.06.007

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  31 in total

1.  Single-voxel proton MRS of the human brain at 1.5T and 3.0T.

Authors:  P B Barker; D O Hearshen; M D Boska
Journal:  Magn Reson Med       Date:  2001-05       Impact factor: 4.668

2.  Deficits of NMDA receptors and glutamate uptake sites in the frontal cortex in AIDS.

Authors:  A M Sardar; P H Hutson; G P Reynolds
Journal:  Neuroreport       Date:  1999-11-26       Impact factor: 1.837

3.  Neuronal and glial metabolite content of the epileptogenic human hippocampus.

Authors:  Ognen A C Petroff; Laura D Errante; Douglas L Rothman; Jung H Kim; Dennis D Spencer
Journal:  Ann Neurol       Date:  2002-11       Impact factor: 10.422

4.  Increased glutamate in CSF and plasma of patients with HIV dementia.

Authors:  C Ferrarese; A Aliprandi; L Tremolizzo; L Stanzani; A De Micheli; A Dolara; L Frattola
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

5.  The AIDS dementia complex: II. Neuropathology.

Authors:  B A Navia; E S Cho; C K Petito; R W Price
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

6.  HIV-associated cognitive impairment before and after the advent of combination therapy.

Authors:  Ned Sacktor; Michael P McDermott; Karen Marder; Giovanni Schifitto; Ola A Selnes; Justin C McArthur; Yaakov Stern; Steve Albert; Donna Palumbo; Karl Kieburtz; Joy A De Marcaida; Bruce Cohen; Leon Epstein
Journal:  J Neurovirol       Date:  2002-04       Impact factor: 2.643

7.  Evidence of reduced glutamate in the frontal lobe of HIV-seropositive patients.

Authors:  Napapon Sailasuta; Kimberly Shriner; Brian Ross
Journal:  NMR Biomed       Date:  2009-04       Impact factor: 4.044

8.  Neocortical damage during HIV infection.

Authors:  C A Wiley; E Masliah; M Morey; C Lemere; R DeTeresa; M Grafe; L Hansen; R Terry
Journal:  Ann Neurol       Date:  1991-06       Impact factor: 10.422

9.  Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120.

Authors:  Zhuying Wang; Olga Pekarskaya; Meryem Bencheikh; Wei Chao; Harris A Gelbard; Anuja Ghorpade; Jeffrey D Rothstein; David J Volsky
Journal:  Virology       Date:  2003-07-20       Impact factor: 3.616

10.  Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients.

Authors:  Linda Chang; Thomas Ernst; Coryse St Hillaire; Katherine Conant
Journal:  Antivir Ther       Date:  2004-06
View more
  41 in total

1.  A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations.

Authors:  Lynn Pulliam; Hans Rempel; Bing Sun; Linda Abadjian; Cyrus Calosing; Dieter J Meyerhoff
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

2.  Loss of neuronal integrity during progressive HIV-1 infection of humanized mice.

Authors:  Prasanta K Dash; Santhi Gorantla; Howard E Gendelman; Jaclyn Knibbe; George P Casale; Edward Makarov; Adrian A Epstein; Harris A Gelbard; Michael D Boska; Larisa Y Poluektova
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

3.  Reliability of White Matter Microstructural Changes in HIV Infection: Meta-Analysis and Confirmation.

Authors:  E E O'Connor; A Jaillard; F Renard; T A Zeffiro
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-08       Impact factor: 3.825

Review 4.  Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain.

Authors:  Linda Chang; Sody M Munsaka; Stephanie Kraft-Terry; Thomas Ernst
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-12       Impact factor: 4.147

Review 5.  Neuroimaging of HIV-associated neurocognitive disorders (HAND).

Authors:  Beau M Ances; Dima A Hammoud
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

6.  A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease.

Authors:  Joseph Scott; Jonathan Underwood; Lucy J Garvey; Borja Mora-Peris; Alan Winston
Journal:  Br J Radiol       Date:  2016       Impact factor: 3.039

7.  Neuropsychological function and cerebral metabolites in HIV-infected youth.

Authors:  R Nagarajan; M K Sarma; M A Thomas; L Chang; U Natha; M Wright; J Hayes; K Nielsen-Saines; D E Michalik; J Deville; J A Church; K Mason; T Critton-Mastandrea; S Nazarian; J Jing; M A Keller
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-13       Impact factor: 4.147

8.  Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy.

Authors:  Assawin Gongvatana; Jaroslaw Harezlak; Steven Buchthal; Eric Daar; Giovanni Schifitto; Thomas Campbell; Michael Taylor; Elyse Singer; Jeffrey Algers; Jianhui Zhong; Mark Brown; Deborah McMahon; Yuen T So; Deming Mi; Robert Heaton; Kevin Robertson; Constantin Yiannoutsos; Ronald A Cohen; Bradford Navia
Journal:  J Neurovirol       Date:  2013-04-24       Impact factor: 2.643

9.  Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND.

Authors:  Thep Chalermchai; Victor Valcour; Pasiri Sithinamsuwan; Suteeraporn Pinyakorn; David Clifford; Robert H Paul; Somporn Tipsuk; James L K Fletcher; Victor Degruttola; Silvia Ratto-Kim; Nicholas Hutchings; Cecilia Shikuma; Jintanat Ananworanich
Journal:  J Neurovirol       Date:  2013-03-13       Impact factor: 2.643

10.  Lower cognitive reserve in the aging human immunodeficiency virus-infected brain.

Authors:  Linda Chang; John L Holt; Renat Yakupov; Caroline S Jiang; Thomas Ernst
Journal:  Neurobiol Aging       Date:  2012-11-15       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.